C19orf66 interrupts Zika virus replication by inducing lysosomal degradation of viral NS3.

• Published in: PLOS Neglected Tropical Diseases
• Main Authors: Yun Wu, Xinyu Yang, Zhicheng Yao, Xinhuai Dong, Danrui Zhang, Yiwen Hu, Shihao Zhang, Jiajie Lin, Jiahui Chen, Shu An, Hengming Ye, Shuqing Zhang, Ziying Qiu, Zhenjian He, Mingxing Huang, Guohong Wei, Xun Zhu
• Format: Article in Journal/Newspaper
• Language: English
• Published: Public Library of Science (PLoS) 2020
• Subjects: Arctic medicine. Tropical medicine; RC955-962; Public aspects of medicine; RA1-1270; Arctic; Human health
• Online Access: https://doi.org/10.1371/journal.pntd.0008083; https://doaj.org/article/596307fe680044f780b8df41effaa312

The rapidly emerging human health crisis associated with the Zika virus (ZIKV) epidemic and its link to severe complications highlights the growing need to identify the mechanisms by which ZIKV accesses hosts. Interferon response protects host cells against viral infection, while the cellular factors that mediate this defense are the products of interferon-stimulated genes (ISGs). Although hundreds of ISGs have been identified, only a few have been characterized for their antiviral potential, target specificity and mechanisms of action. In this work, we focused our investigation on the possible antiviral effect of a novel ISG, C19orf66 in response to ZIKV infection and the associated mechanisms. We found that ZIKV infection could induce C19orf66 expression in ZIKV-permissive cells, and such an overexpression of C19orf66 remarkably suppressed ZIKV replication. Conversely, the depletion of C19orf66 led to a significant increase in viral replication. Furthermore, C19orf66 was found to interact and co-localize with ZIKV nonstructural protein 3 (NS3), thus inducing NS3 degradation via a lysosome-dependent pathway. Taken together, this study identified C19orf66 as a novel ISG that exerts antiviral effects against ZIKV by specifically degrading a viral nonstructural protein. These findings uncovered an intriguing mechanism of C19orf66 that targeting NS3 protein of ZIKV, providing clues for understanding the actions of innate immunity, and affording the possible availability of new drug targets that can be used for therapeutic intervention.